Table 4.
Adjusted HRs (95% CIs) for inpatient VTE outcome comparing DOAC users to matched control users for the treatment of nonvalvular AF in active cancer patients, MarketScan, 2010-2014
| No. of events | Person-years | No. of events | Person-years | HR (95% CI) | P | |
|---|---|---|---|---|---|---|
| DOAC | Warfarin | |||||
| Rivaroxaban vs warfarin | 66 | 2085 | 160 | 4156 | 0.73 (0.53, 1.01) | .06 |
| Dabigatran vs warfarin | 28 | 3217 | 281 | 8734 | 0.38 (0.25, 0.57) | <.0001 |
| Apixaban vs warfarin | 2 | 541 | 67 | 1407 | 0.14 (0.03, 0.59) | .008 |
| DOAC | Rivaroxaban | |||||
| Dabigatran vs rivaroxaban | 6 | 961 | 15 | 997 | 0.37 (0.11, 1.21) | .10 |
| Apixaban vs rivaroxaban | 2 | 558 | 43 | 1004 | 0.08 (0.02, 0.35) | .0008 |
Adjusted for age, sex, CHA2DS2-VASc score, prior history of the outcome, and HDPS. Bold values represent statistical significance.